Literature DB >> 16517873

Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.

Kimberly P Liang1, Imad M Tleyjeh, Walter R Wilson, Glenn D Roberts, Zelalem Temesgen.   

Abstract

Rhino-orbitocerebral mucormycosis (ROCM) caused by more common zygomycetes (e.g., Mucor) is known to cause rapidly fatal infections in immunocompromised patients. Apophysomyces elegans is an emerging zygomycete that has been reported to cause invasive cutaneous and rhino-orbitocerebral infections in immunocompetent individuals. Limited data exist describing the syndrome of ROCM caused by A. elegans. We describe a recent case and performed a comprehensive literature review to delineate the clinical characteristics of ROCM caused by A. elegans. Our case is a 50-year-old man with diabetes mellitus who presented with facial pain and right eye proptosis. Endoscopic sinus sampling revealed A. elegans. He was treated with liposomal amphotericin B and multiple debridements, with no disease on 1.5-year follow-up examination. Seven cases were identified on literature review, including the present case. Most patients (86%) were male, with a mean age of 40 years. Most patients (71%) did not have predisposing medical conditions. Three patients had predisposing head trauma. All presented with facial and/or periorbital pain. All had magnetic resonance imaging or computed tomography of the head showing intraorbital and/or sinus inflammation. Diagnosis was confirmed by histopathology and deep tissue culture in all cases. All patients required eye exenteration and extensive surgical debridement, in addition to intravenous amphotericin B. Six of the seven patients (86%) recovered. ROCM caused by A. elegans is rarely reported in the literature. Most such infections occurred in immunocompetent patients, often after facial trauma. Survival in ROCM caused by A. elegans is favorable in reported cases, with prompt surgical debridement and antifungal therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517873      PMCID: PMC1393113          DOI: 10.1128/JCM.44.3.892-898.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Severe cutaneous mucormycosis (Zygomycosis) due to Apophysomyces elegans.

Authors:  R Page; D J Gardam; C H Heath
Journal:  ANZ J Surg       Date:  2001-03       Impact factor: 1.872

Review 2.  Rhino-orbitocerebral mucormycosis attributable to Apophysomyces elegans in an immunocompetent individual: case report and review of the literature.

Authors:  L Garcia-Covarrubias; R Bartlett; D M Barratt; R J Wassermann
Journal:  J Trauma       Date:  2001-02

3.  Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.

Authors:  Angela Ma Tobón; Myrtha Arango; Darío Fernández; Angela Restrepo
Journal:  Clin Infect Dis       Date:  2003-05-16       Impact factor: 9.079

Review 4.  Locally invasive cutaneous Apophysomyces elegans infection acquired from snapdragon patch test.

Authors:  Janis E Blair; Lorna J Fredrikson; Barbara A Pockaj; Christina S Lucaire
Journal:  Mayo Clin Proc       Date:  2002-07       Impact factor: 7.616

5.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Necrotizing cellulitis caused by Apophysomyces elegans at a patch test site.

Authors:  Benjamin W Lesueur; Karen Warschaw; Lorna Fredrikson
Journal:  Am J Contact Dermat       Date:  2002-09

7.  Apophysomyces elegans: an emerging zygomycete in India.

Authors:  A Chakrabarti; A Ghosh; G S Prasad; J K David; S Gupta; A Das; V Sakhuja; N K Panda; S K Singh; S Das; T Chakrabarti
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

8.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Widespread cutaneous involvement by invasive Apophysomyces elegans in a gravid patient following trauma.

Authors:  J Elliot Carter; Ozlem Ulusarac
Journal:  Cutis       Date:  2003-09

10.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  18 in total

1.  Evidence implicating Thamnostylum lucknowense as an etiological agent of rhino-orbital mucormycosis.

Authors:  Immaculata Xess; Sarita Mohapatra; M R Shivaprakash; Arunaloke Chakrabarti; Gerald L Benny; Kerry O'Donnell; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

2.  Invasive Apophysomyces variabilis infection in a burn patient.

Authors:  Wilfred P dela Cruz; Tatjana P Calvano; Matthew E Griffith; Christopher E White; Seung H Kim; Deanna A Sutton; Elizabeth H Thompson; Jianmin Fu; Brian L Wickes; Josep Guarro; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

3.  Apophysomyces elegans: a novel cause of endogenous endophthalmitis in an immunocompetent individual.

Authors:  Vivek Pravin Dave; Savitri Sharma; Rohit Yogi; Swapna Reddy
Journal:  Int Ophthalmol       Date:  2014-09-03       Impact factor: 2.031

Review 4.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Amphotericin B Resistant Apophysomyces elegans Causing Rhino-oculo-Cerebral Mucormycosis in an Immunocompetent Host.

Authors:  Debasis Biswas; Aarti Kotwal; Barnali Kakati; Sohaib Ahmad
Journal:  J Clin Diagn Res       Date:  2015-08-01

Review 6.  A case of rhinoorbital mucormycosis in a leukemic patient with a literature review from Turkey.

Authors:  Ramazan Gumral; Uzeyir Yildizoglu; Mehmet Ali Saracli; Kursat Kaptan; Fuat Tosun; Sinasi Taner Yildiran
Journal:  Mycopathologia       Date:  2011-07-15       Impact factor: 2.574

7.  Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

Authors:  A Chakrabarti; M R Shivaprakash; I Curfs-Breuker; A Baghela; C H Klaassen; J F Meis
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

8.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

9.  Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis.

Authors:  Nilay Kumar; Mary E Hanks; Prabha Chandrasekaran; Brian C Davis; Amy P Hsu; Nicholas J Van Wagoner; Jessica S Merlin; Christine Spalding; Ricardo M La Hoz; Steven M Holland; Christa S Zerbe; Elizabeth P Sampaio
Journal:  J Allergy Clin Immunol       Date:  2014-04-04       Impact factor: 10.793

10.  Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Authors:  Dounia Bitar; Dieter Van Cauteren; Fanny Lanternier; Eric Dannaoui; Didier Che; Francoise Dromer; Jean Claude Desenclos; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.